Pim3 up-regulation by YY1 contributes to diabetes-induced cardiac hypertrophy and heart failure

Document Type : Original Article

Authors

Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China

10.22038/ijbms.2024.78688.17016

Abstract

Objective(s): The close relationship of proto-oncogenes to myocardial hypertrophy has long been recognized, and cardiac hypertrophy leads to heart failure (HF). However, whether proviral insertion of Moloney virus 3 kinase (Pim3), a proto-oncogene, contributes to cardiac hypertrophy in diabetes mellitus (DM) remains unknown. This study aims to investigate whether Pim3 is involved in DM-induced cardiac hypertrophy and HF and to elucidate its underlying mechanisms.
Materials and Methods: DM was induced in mice by intraperitoneal injection of streptozotocin. Cardiac function was evaluated by echocardiography, and cardiac hypertrophy was determined through histological analysis, quantitative real-time polymerase chain reaction, and western blotting. Silencing RNA transfection and lentivirus-mediated gene knockdown were performed both in vitro and in vivo. Transcriptional activity was analyzed using chromatin immunoprecipitation and luciferase reporter assay.
Results: Compared with C57BL/6J mice, cardiac hypertrophy and dysfunction were observed in mice with DM. Pim3 mRNA and protein expression were significantly up-regulated in diabetic hearts and high glucose-cultured H9C2 cells. Yin Yang 1 (YY1), which translocated from the cytoplasm into the nucleus under hyperglycemia, bound to the Pim3 promoter and enhanced Pim3 transcriptional activity. Pim3 or YY1 knockdown profoundly reduced cell size and inhibited the mRNA and protein expression of cardiac hypertrophy markers, as well as markedly attenuating myocardial hypertrophy and cardiac dysfunction.
Conclusion: Hyperglycemia induced nuclear translocation of YY1, leading to Pim3 up-regulation, eventually developing into cardiac hypertrophy and HF. Targeting YY1-Pim3 signaling may be a promising therapeutic avenue for DM-induced cardiac hypertrophy and HF.

Keywords

Main Subjects

References

1. Ge W, Hou C, Zhang W, Guo X, Gao P, Song X, et al. Mep1a contributes to Ang II-induced cardiac remodeling by promoting cardiac hypertrophy, fibrosis and inflammation. J Mol Cell Cardiol 2021; 152: 52-68.
2. Zhang Y, Da Q, Cao S, Yan K, Shi Z, Miao Q, et al. HINT1 (histidine triad nucleotide-binding protein 1) attenuates cardiac hypertrophy via suppressing HOXA5 (Homeobox A5) expression. Circulation 2021; 144: 638-654.
3. Tang X, Pan L, Zhao S, Dai F, Chao M, Jiang H, et al. SNO-MLP (S-nitrosylation of muscle LIM protein) facilitates myocardial hypertrophy through TLR3 (toll-like receptor 3)-mediated RIP3 (receptor-interacting protein kinase 3) and NLRP3 (NOD-like receptor pyrin domain containing 3) inflammasome activation. Circulation 2020; 141: 984-1000.
4. Park JJ. Epidemiology, pathophysiology, diagnosis and treatment of heart failure in diabetes. Diabetes Metab J 2021; 45: 146-157.
5. Cibi DM, Sandireddy R, Bogireddi H, Tee N, Ghani S, Singh BK, et al. Cardiac tissue factor regulates inflammation, hypertrophy, and heart failure in mouse model of type 1 diabetes. Diabetes 2021; 70: 2131-2146.
6. Xu Q, Ding H, Li S, Dong S, Li L, Shi B, et al. Sleeve gastrectomy ameliorates diabetes-induced cardiac hypertrophy correlates with the MAPK signaling pathway. Front Physiol 2021; 12: 785799-785812.
7. Asghari AA, Mahmoudabady M, Mousavi Emadi Z, Hosseini SJ, Salmani H. Cardiac hypertrophy and fibrosis were attenuated by olive leaf extract treatment in a rat model of diabetes. J Food Biochem 2022; 46: e14494.
8. Farazandeh M, Mahmoudabady M, Asghari AA, Niazmand S. Diabetic cardiomyopathy was attenuated by cinnamon treatment through the inhibition of fibro-inflammatory response and ventricular hypertrophy in diabetic rats. J Food Biochem 2022; 46: e14206.
9. Oceandy D, Cartwright EJ, Neyses L. Ras-association domain family member 1A (RASSF1A)-where the heart and cancer meet. Trends Cardiovasc Med 2009; 19: 262-267.
10. Liu DX, Liu XM, Su Y, Zhang XJ. Renal expression of proto-oncogene Ets-1 on matrix remodeling in experimental diabetic nephropathy. Acta Histochem 2011; 113: 527-533.
11. Kowluru RA, Kowluru A, Chakrabarti S, Khan Z. Potential contributory role of H-Ras, a small G-protein, in the development of retinopathy in diabetic rats. Diabetes 2004; 53: 775-783.
12. Mikkers H, Nawijn M, Allen J, Brouwers C, Verhoeven E, Jonkers J, et al. Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors. Mol Cell Biol 2004; 24: 6104-6115.
13. Katare RG, Caporali A, Oikawa A, Meloni M, Emanueli C, Madeddu P. Vitamin B1 analog benfotiamine prevents diabetes-induced diastolic dysfunction and heart failure through Akt/Pim-1-mediated survival pathway. Circ Heart Fail 2010; 3: 294-305.
14. Katare R, Caporali A, Zentilin L, Avolio E, Sala-Newby G, Oikawa A, et al. Intravenous gene therapy with PIM-1 via a cardiotropic viral vector halts the progression of diabetic cardiomyopathy through promotion of prosurvival signaling. Circ Res 2011; 108: 1238-1251.
15. Moore A, Shindikar A, Fomison-Nurse I, Riu F, Munasinghe PE, Ram TP, et al. Rapid onset of cardiomyopathy in STZ-induced female diabetic mice involves the downregulation of pro-survival Pim-1. Cardiovasc Diabetol 2014; 13: 68-79.
16. Xu Y, Xing Y, Xu Y, Huang C, Bao H, Hong K, et al. Pim-2 protects H9c2 cardiomyocytes from hypoxia/reoxygenation-induced apoptosis via downregulation of Bim expression. Environ Toxicol Pharmacol 2016; 48:94-102.
17. Yao M, Li L, Huang M, Tan Y, Shang Y, Meng X, et al. Sanye tablet ameliorates insulin resistance and dysregulated lipid metabolism in high-fat diet-induced obese mice. Front Pharmacol 2021; 12: 713750-713765.
18. Gordon S, Akopyan G, Garban H, Bonavida B. Transcription factor YY1: Structure, function, and therapeutic implications in cancer biology. Oncogene 2006; 25: 1125-1142.
19. Asensio-Lopez MC, Lax A, Fernandez del Palacio MJ, Sassi Y, Hajjar RJ, Januzzi JL, et al. Yin-Yang 1 transcription factor modulates ST2 expression during adverse cardiac remodeling post-myocardial infarction. J Mol Cell Cardiol 2019; 130: 216-233.
20. Stauffer BL, Dockstader K, Russell G, Hijmans J, Walker L, Cecil M, et al. Transgenic over-expression of YY1 induces pathologic cardiac hypertrophy in a sex-specific manner. Biochem Biophys Res Commun 2015; 462: 131-137.
21. Fujino M, Morito N, Hayashi T, Ojima M, Ishibashi S, Kuno A, et al. Transcription factor c-Maf deletion improves streptozotocin-induced diabetic nephropathy by directly regulating Sglt2 and Glut2. JCI Insight 2023; 8: e163306-163323.
22. Zuo GF, Wang LG, Huang L, Ren YF, Ge Z, Hu ZY, et al. TAX1BP1 downregulation by STAT3 in cardiac fibroblasts contributes to diabetes-induced heart failure with preserved ejection fraction. Biochim Biophys Acta Mol Basis Dis 2024; 1870:166979.
23. Nan J, Hu H, Sun Y, Zhu L, Wang Y, Zhong Z, et al. TNFR2 stimulation promotes mitochondrial fusion via Stat3- and NF-kB-dependent activation of OPA1 expression. Circ Res 2017; 121:392-410.
24. Zhou S, Dai Q, Huang X, Jin A, Yang Y, Gong X, et al. STAT3 is critical for skeletal development and bone homeostasis by regulating osteogenesis. Nat Commun 2021; 12: 6891-6907.
25. Liu Z, Yao X, Yan G, Xu Y, Yan J, Zou W, et al. Mediator MED23 cooperates with RUNX2 to drive osteoblast differentiation and bone development. Nat Commun 2016; 7: 11149-11159.
26. Triposkiadis F, Xanthopoulos A, Parissis J, Butler J, Farmakis D. Pathogenesis of chronic heart failure: Cardiovascular aging, risk factors, comorbidities, and disease modifiers. Heart Fail Rev 2022; 27: 337-344.
27. Lei B, Chess DJ, Keung W, O’Shea KM, Lopaschuk GD, Stanley WC. Transient activation of p38 MAP kinase and up-regulation of Pim-1 kinase in cardiac hypertrophy despite no activation of AMPK. J Mol Cell Cardiol 2008; 45: 404-410.
28. Wang K, Deng X, Shen Z, Jia Y, Ding R, Li R, et al. High glucose promotes vascular smooth muscle cell proliferation by upregulating proto-oncogene serine/threonine-protein kinase Pim-1 expression. Oncotarget 2017; 8: 88320-88331.
29. Din S, Konstandin MH, Johnson B, Emathinger J, Volkers M, Toko H, et al. Metabolic dysfunction consistent with premature aging results from deletion of Pim kinases. Circ Res 2014; 115:376-387.
30. Beharry Z, Mahajan S, Zemskova M, Lin YW, Tholanikunnel BG, Xia Z, et al. The Pim protein kinases regulate energy metabolism and cell growth. Proc Natl Acad Sci U S A 2011; 108: 528-533.
31. van Lunteren E, Moyer M. Oxidoreductase, morphogenesis, extracellular matrix, and calcium ion-binding gene expression in streptozotocin-induced diabetic rat heart. Am J Physiol Endocrinol Metab 2007; 293: E759-768.
32. Sucharov CC, Mariner P, Long C, Bristow M, Leinwand L. Yin Yang 1 is increased in human heart failure and represses the activity of the human alpha-myosin heavy chain promoter. J Biol Chem 2003; 278: 31233-31239.
33. Huang Y, Li L, Chen H, Liao Q, Yang X, Yang D, et al. The protective role of yin-yang 1 in cardiac injury and remodeling after myocardial infarction. J Am Heart Assoc 2021; 10: e021895-21917.
34. Sucharov CC, Dockstader K, McKinsey TA. YY1 protects cardiac myocytes from pathologic hypertrophy by interacting with HDAC5. Mol Biol Cell 2008; 19: 4141-4153.
35. Phang RJ, Ritchie RH, Hausenloy DJ, Lees JG, Lim SY. Cellular interplay between cardiomyocytes and non-myocytes in diabetic cardiomyopathy. Cardiovasc Res 2023; 119: 668-690. 
 
Iranian Journal of Basic Medical Sciences
Volume 28, Issue 2
February 2025
Pages 245-253

Files

Share

How to cite

Statistics